| 2027-01-01in 129 d | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | 4568.TDaiichi Sankyo Co., Ltd. | Phase 1 | Breast Cancer | Active, not recruiting |
| 2027-01-01in 129 d | CONVERGE Post-Approval Study (PAS) | ATRCAtriCure, Inc. | Not applicable | Chronic Atrial Fibrillation | Active, not recruiting |
| 2027-01-01in 129 d | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | INCYIncyte Corporation | Phase 1 | Solid Tumors | Recruiting |
| 2027-01-01in 129 d | Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS | SIGASIGA Technologies | Phase 2 | Smallpox | Active, not recruiting |
| 2027-01-04in 132 d | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | AZNAstraZeneca | Phase 3 | Heterozygous Familial Hypercholesterolaemia | Active, not recruiting |
| 2027-01-04in 132 d | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease | INCYIncyte Corporation | Phase 1 | Renal Impairment | Recruiting |
| 2027-01-06in 134 d | A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | AMGNAmgen | Phase 1/2 | Thyroid Eye Disease | Active, not recruiting |
| 2027-01-06in 134 d | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | AZNAstraZeneca | Phase 3 | Systemic Sclerosis | Active, not recruiting |
| 2027-01-06in 134 d | A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease | BMYBristol-Myers Squibb | Phase 1/2 | Sickle Cell Disease | Recruiting |
| 2027-01-06in 134 d | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | INCYIncyte Corporation | Phase 1/2 | Graft-Versus-Host Disease | Active, not recruiting |
| 2027-01-06in 134 d | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | REGNRegeneron Pharmaceuticals | Phase 1 | Solid Tumors | Recruiting |
| 2027-01-07in 135 d | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | IDYAIDEAYA Biosciences | Phase 1 | Solid Tumors | Active, not recruiting |
| 2027-01-07in 135 d | Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | SNYSanofi | Phase 3 | Sickle Cell Disease | Recruiting |
| 2027-01-08in 136 d | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | OCULOcular Therapeutix, Inc. | Phase 3 | Age-Related Macular Degeneration | Active, not recruiting |
| 2027-01-08in 136 d | A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | SNYSanofi | Phase 2 | Plasma Cell Myeloma Refractory | Recruiting |
| 2027-01-11in 139 d | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | AZNAstraZeneca | Phase 3 | Cardiovascular Disease | Active, not recruiting |
| 2027-01-13in 141 d | A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | AZNAstraZeneca | Phase 3 | Chronic Rhinosinusitis | Active, not recruiting |
| 2027-01-13in 141 d | A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity | PFEPfizer | Phase 1 | Overweight | Not yet recruiting |
| 2027-01-14in 142 d | A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity | NVONovo Nordisk A/S | Phase 2 | Overweight | Recruiting |
| 2027-01-15in 143 d | A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity | AZTRAzitra Inc. | Phase 1/2 | EGFR Inhibitor-associated Rash | Recruiting |
| 2027-01-15in 143 d | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | IDYAIDEAYA Biosciences | Phase 2/3 | Metastatic Uveal Melanoma | Active, not recruiting |
| 2027-01-15in 143 d | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | MLTXMoonLake Immunotherapeutics AG | Phase 3 | Psoriatic Arthritis | Recruiting |
| 2027-01-15in 143 d | A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure | NVONovo Nordisk A/S | Phase 1 | Heart Failure | Recruiting |
| 2027-01-15in 143 d | Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | XBITXBiotech, Inc. | Phase 2 | Rheumatoid Arthritis | Not yet recruiting |
| 2027-01-16in 144 d | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | CRBPCorbus Pharmaceuticals Inc. | Phase 1/2 | Solid Tumors | Recruiting |
| 2027-01-18in 146 d | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | AZNAstraZeneca | Phase 2 | Lung Cancer | Active, not recruiting |
| 2027-01-18in 146 d | Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | PFEPfizer | Phase 3 | Lower Respiratory Tract Illness | Active, not recruiting |
| 2027-01-19in 147 d | A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors | BMYBristol-Myers Squibb | Phase 1 | Solid Tumors | Recruiting |
| 2027-01-19in 147 d | A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | SNYSanofi | Phase 1/2 | Solid Tumors | Recruiting |
| 2027-01-20in 148 d | A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants | BMYBristol-Myers Squibb | — | Multiple Sclerosis | Active, not recruiting |
| 2027-01-20in 148 d | Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain | CELZCreative Medical Technology Holdings Inc | Phase 1/2 | Chronic Low-back Pain, Degenerative Disc Disease | Active, not recruiting |
| 2027-01-20in 148 d | A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar | NVONovo Nordisk A/S | — | Type 1 Diabetes | Active, not recruiting |
| 2027-01-21in 149 d | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | AMGNAmgen | Phase 3 | Obesity | Active, not recruiting |
| 2027-01-21in 149 d | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | AMGNAmgen | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Active, not recruiting |
| 2027-01-21in 149 d | A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity | NVONovo Nordisk A/S | Phase 1 | Overweight | Recruiting |
| 2027-01-21in 149 d | An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) | REGNRegeneron Pharmaceuticals | — | Atopic Dermatitis | Recruiting |
| 2027-01-21in 149 d | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | TGTXTG Therapeutics, Inc. | Phase 3 | Multiple Sclerosis | Recruiting |
| 2027-01-22in 150 d | ATGAM General Investigation | PFEPfizer | — | Aplastic Anemia | Active, not recruiting |
| 2027-01-23in 151 d | Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | AMGNAmgen | Phase 4 | Osteoporosis | Active, not recruiting |
| 2027-01-24in 152 d | Korea Comirnaty Post-marketing Surveillance | PFEPfizer | — | COVID-19 | Active, not recruiting |
| 2027-01-25in 153 d | A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | NVONovo Nordisk A/S | Phase 3 | Type 1 Diabetes | Recruiting |
| 2027-01-25in 153 d | A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF | PFEPfizer | Phase 3 | Respiratory Syncytial Virus | Recruiting |
| 2027-01-25in 153 d | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Diabetic Peripheral Neuropathic Pain | Active, not recruiting |
| 2027-01-26in 154 d | A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese | NVONovo Nordisk A/S | Phase 1 | Overweight | Recruiting |
| 2027-01-27in 155 d | A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | PFEPfizer | Phase 1 | Obesity | Active, not recruiting |
| 2027-01-27in 155 d | Pacritinib Effectiveness in Real-world Settings | SOBI.STSwedish Orphan Biovitrum | — | Myelofibrosis | Not yet recruiting |
| 2027-01-28in 156 d | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | MRNAModernaTX, Inc. | Phase 3 | Influenza | Active, not recruiting |
| 2027-01-29in 157 d | A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | AZNAstraZeneca | Phase 1/2 | Obesity | Active, not recruiting |
| 2027-01-29in 157 d | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC | AZNAstraZeneca | Phase 1 | Renal Cell Carcinoma | Active, not recruiting |
| 2027-01-29in 157 d | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | IDYAIDEAYA Biosciences | Phase 1/2 | Melanoma | Recruiting |
| 2027-01-29in 157 d | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | PFESeagen, a wholly owned subsidiary of Pfizer | Phase 3 | Urothelial Carcinoma | Active, not recruiting |
| 2027-01-30in 158 d | A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) | BMYBristol-Myers Squibb | Phase 1/2 | Relapsed or Refractory T-cell Lymphomas | Active, not recruiting |
| 2027-01-30in 158 d | A Retrospective Review: Outcomes of the REFLECT™ System for Idiopathic Scoliosis | GMEDGlobus Medical Inc | — | Idiopathic Scoliosis | Not yet recruiting |
| 2027-01-30in 158 d | Enhancing Heart Allograft Function With the OCS Heart System Trial | TMDXTransMedics | Not applicable | Heart Transplant | Recruiting |
| 2027-01-30in 158 d | Evaluation of Pain Treatment After Total Knee Arthroplasty | VRTXVertex Pharmaceuticals Incorporated | Phase 4 | Pain | Recruiting |
| 2027-01-31in 159 d | Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | 4568.TDaiichi Sankyo Co., Ltd. | Phase 2 | Duchenne Muscular Dystrophy | Active, not recruiting |
| Jan 2027≤ 159 d | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | ABBVAbbVie | Phase 1 | Myelofibrosis | Active, not recruiting |
| Jan 2027≤ 159 d | An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease | ABBVAbbVie | — | Parkinson's Disease | Active, not recruiting |
| Jan 2027≤ 159 d | Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | ABBVAbbVie | Phase 3 | Atopic Dermatitis | Active, not recruiting |
| Jan 2027≤ 159 d | A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa | ABBVAbbVie | — | Parkinson's Disease | Recruiting |
| Jan 2027≤ 159 d | A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Recruiting |
| Jan 2027≤ 159 d | A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity. | ABBVAbbVie | Phase 1 | Healthy Volunteer | Active, not recruiting |
| 2027-01-31in 159 d | Cryoablation for Monomorphic Ventricular Tachycardia | ADGMAdagio Medical | Not applicable | Sustained VT | Active, not recruiting |
| Jan 2027≤ 159 d | Inappropriate Sinus Tachycardia Registry | ATRCAtriCure, Inc. | — | Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome | Recruiting |
| 2027-01-31in 159 d | A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region | AZNAstraZeneca | — | Hematology, Diffused Large B Cell Lymphoma | Recruiting |
| 2027-01-31in 159 d | Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP) | AZNAstraZeneca | — | Lung Cancer | Not yet recruiting |
| Jan 2027≤ 159 d | Personal BP - CAI Study | BDXBecton, Dickinson and Company | Not applicable | Blood Pressure | Recruiting |
| Jan 2027≤ 159 d | The Continuity Study | BDXBecton, Dickinson and Company | Not applicable | Blood Pressure | Recruiting |
| 2027-01-31in 159 d | A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children | BLCOBausch & Lomb Incorporated | Not applicable | Myopia | Recruiting |
| 2027-01-31in 159 d | A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring | BMYBristol-Myers Squibb | — | Psoriasis | Active, not recruiting |
| 2027-01-31in 159 d | Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | CELZCreative Medical Technology Holdings Inc | Phase 1/2 | Type 1 Diabetes | Recruiting |
| Jan 2027≤ 159 d | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | CGEMCullinan Therapeutics Inc. | Phase 1 | Acute Myeloid Leukemia | Recruiting |
| Jan 2027≤ 159 d | Study of COYA 302 for the Treatment of ALS | COYACoya Therapeutics | Phase 2/3 | Amyotrophic Lateral Sclerosis (ALS) | Recruiting |
| Jan 2027≤ 159 d | Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) | CPIXCumberland Pharmaceuticals | Phase 2 | Idiopathic Pulmonary Fibrosis | Recruiting |
| Jan 2027≤ 159 d | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant | ELDNEledon Pharmaceuticals | Phase 1/2 | Prevention of Rejection in Kidney Transplant | Recruiting |
| Jan 2027≤ 159 d | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | ELVNEnliven Therapeutics | Phase 1 | Breast Cancer | Active, not recruiting |
| Jan 2027≤ 159 d | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | EWTXEdgewise Therapeutics, Inc. | Phase 2 | Duchenne Muscular Dystrophy | Active, not recruiting |
| 2027-01-31in 159 d | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | EXELExelixis | Phase 1 | Renal Cell Carcinoma | Recruiting |
| Jan 2027≤ 159 d | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | GILDGilead Sciences | Phase 2 | Ulcerative Colitis | Recruiting |
| Jan 2027≤ 159 d | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | KURAKura Oncology, Inc. | Phase 1 | Lung Cancer | Recruiting |
| Jan 2027≤ 159 d | A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer | LLYEli Lilly and Company | Phase 1 | Neoplasms, Healthy | Recruiting |
| Jan 2027≤ 159 d | A Study of LY4355756 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Not yet recruiting |
| Jan 2027≤ 159 d | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | LRMRLarimar Therapeutics, Inc. | Phase 2 | Friedreich Ataxia | Recruiting |
| Jan 2027≤ 159 d | Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds | MDXGMiMedx Group, Inc. | Not applicable | Diabetic Foot Ulcer, Venous Leg Ulcer | Recruiting |
| Jan 2027≤ 159 d | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | NBIXNeurocrine Biosciences | Phase 4 | Schizophrenia | Recruiting |
| Jan 2027≤ 159 d | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | NRIXNurix Therapeutics, Inc. | Phase 1 | Chronic Lymphocytic Leukemia | Recruiting |
| Jan 2027≤ 159 d | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | NUVLNuvalent Inc. | Phase 1 | Solid Tumors | Recruiting |
| Jan 2027≤ 159 d | ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose | ORKAOruka Therapeutics, Inc. | Phase 1 | Healthy Volunteers | Active, not recruiting |
| Jan 2027≤ 159 d | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 | PCVXVaxcyte, Inc. | Phase 3 | Pneumococcal Disease | Active, not recruiting |
| 2027-01-31in 159 d | A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | PFEPfizer | — | COVID-19 | Active, not recruiting |
| Jan 2027≤ 159 d | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | PRAXPraxis Precision Medicines | Phase 3 | Epilepsy and Seizure Disorders | Active, not recruiting |
| 2027-01-31in 159 d | Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | QNRXQuoin Pharmaceuticals | Phase 2/3 | Netherton Syndrome | Recruiting |
| Jan 2027≤ 159 d | Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta | RAREUltragenyx Pharmaceutical Inc | Phase 3 | Osteogenesis Imperfecta | Active, not recruiting |
| Jan 2027≤ 159 d | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | RCUSArcus Biosciences, Inc. | Phase 2 | Gastrointestinal Tract Malignancies | Active, not recruiting |
| 2027-01-31in 159 d | SAD Study in Patients With Parkinson's Disease and Motor Fluctuations | SERSerina Therapeutics | Phase 1 | Parkinson's Disease | Recruiting |
| Jan 2027≤ 159 d | Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | SGMTSagimet Biosciences Inc. | Phase 1 | Acne | Recruiting |
| Jan 2027≤ 159 d | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease | TCRXTScan Therapeutics, Inc. | — | Ulcerative Colitis | Recruiting |
| Jan 2027≤ 159 d | An Open-Label Study of Azetukalner in Major Depressive Disorder | XENEXenon Pharmaceuticals Inc. | Phase 3 | Major Depressive Disorder | Enrolling by invitation |
| Jan 2027≤ 159 d | PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | ZBHZimmer Biomet | — | Osteoarthritis | Active, not recruiting |
| Jan 2027≤ 159 d | ZNN Bactiguard Antegrade Femoral Nails PMCF Study | ZBHZimmer Biomet | — | Femur Fracture, Osteotomy | Recruiting |
| Jan 2027≤ 159 d | ROSA Knee Intraoperative Planning Flexibility Study | ZBHZimmer Biomet | — | Rheumatoid Arthritis | Recruiting |
